Claims for Patent: 9,688,765

Summary for Patent: 9,688,765

Title:	Methods using RANK/RANKL antagonist antibodies for treating pain
Abstract:	Disclosed herein are methods of treating pain using comprising RANK/RANKL antagonists.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	15/269,799
Patent Claims:	1. A method of treating or relieving osteoarthritis pain, low back pain, or pain from complex regional pain syndrome in a mammal in need thereof, comprising administering an antibody to the mammal, wherein the antibody: a) is denosumab; or b) has binding specificity to RANKL and competes with denosumab for binding to RANKL. 2. The method of claim 1, wherein the antibody is a monoclonal antibody. 3. The method of claim 2 wherein the monoclonal antibody is a human antibody, a humanized antibody, or a chimeric antibody. 4. The method of claim 1, wherein the antibody has binding specificity to RANKL. 5. The method of claim 1, wherein about 0.05 mg/kg to about 3 mg/kg of the antibody is administered to the mammal being within a four week period. 6. The method of claim 5, where about 0.1 mg/kg to about 20 mg/kg of the antibody is administered. 7. The method of claim 1, wherein the antibody is administered no more than once a week. 8. The method of claim 1, wherein the antibody is administered daily, weekly, monthly, every three months, every six months, or every year. 9. The method of claim 1, wherein the method is a method of relieving osteoarthritis pain. 10. The method of claim 9, wherein the osteoarthritis affects a knee. 11. The method of claim 1, wherein the method is a method of relieving pain from complex regional pain syndrome. 12. The method of claim 1, wherein the method is a method of relieving low back pain. 13. The method of claim 1, wherein the antibody comprises a) a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 3; and b) a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 4. 14. The method of claim 1, wherein the mammal experiences pain relief within about three months after the antibody is first administered. 15. The method of claim 1, wherein the antibody comprises a RANKL-binding fragment. 16. The method of claim 15, wherein the RANKL-binding fragment is a Fab, a Fab', a F(ab').sub.2, a Fv fragment, a diabody, a linear antibody, or a single-chain antibody molecule. 17. The method of claim 1, wherein the antibody partially or fully blocks, inhibits, or neutralizes a biological activity of RANKL. 18. The method of claim 1, wherein the mammal experiences pain relief for at least 24 hours. 19. The method of claim 1, wherein the antibody is denosumab. 20. The method of claim 1, wherein the antibody has binding specificity to RANKL and competes with denosumab for binding to RANKL. 21. The method of claim 1, wherein the mammal is a human being. 22. The method of claim 1, wherein the antibody that has binding specificity to RANKL and competes with denosumab for binding to RANKL has at least about 90% sequence identity to denosumab. 23. The method of claim 1, wherein the antibody that has binding specificity to RANKL and competes with denosumab for binding to RANKL has at least about 95% sequence identity to denosumab. 24. The method of claim 1, wherein the antibody that has binding specificity to RANKL and competes with denosumab for binding to RANKL; has at least about 99% sequence identity to denosumab.

Details for Patent 9,688,765

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	PROLIA	denosumab	Injection	125320	06/01/2010		2034-06-11
Amgen, Inc.	XGEVA	denosumab	Injection	125320	11/18/2010		2034-06-11